Mar, 22 2019 11:23 JST

Source: Eisai

Eisai to Present Latest Research on Alzheimer's Disease / Dementia Pipeline at the 14th International Conference on Alzheimer's & Parkinson's Diseases


TOKYO, Mar, 22 2019 - (JCN Newswire) - Eisai Co., Ltd. announced that a total of seven presentations highlighting the latest data on its Alzheimer's disease/dementia pipeline, including anti-amyloid beta (Abeta) protofibril antibody BAN2401 and oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat will be given at the 14th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD) from March 26 to 31 in Lisbon, Portugal. BAN2401 and elenbecestat are being jointly developed by Eisai and Biogen Inc.

Five of the presentations will be given for BAN2401 and elenbecestat. The presentations include the study design for the Open Label Extension (OLE) portion of the BAN2401 Phase II clinical study in patients with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's disease (collectively known as early Alzheimer?s disease) with confirmed amyloid pathology in the brain.

There will be a presentation of electrocardiogram (ECG) data to inform dose selection for E2027, a phosphodiesterase-9 (PDE9) inhibitor, discovered and developed solely by Eisai, in a Phase II study for dementia with Lewy bodies.

Eisai is aiming to realize prevention and cure of dementia through a holistic approach to dementia drug discovery research based on a foundation of over 30 years of experience of drug discovery activities in the area of Alzheimer's disease/dementia. Eisai is striving to create innovative medicines as soon as possible in order to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, patients and their families.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Japan MHLW Grants Sakigake Designation to Novel Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor E7090
April 08 2019 13:06 JST
 
Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor
April 08 2019 10:43 JST
 
Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug
April 05 2019 09:45 JST
 
Eisai: Data Safety Monitoring Board Recommends Continuation of Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease
March 29 2019 10:46 JST
 
Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease
March 22 2019 10:37 JST
 
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease
March 21 2019 23:25 JST
 
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
March 12 2019 07:43 JST
 
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan
March 07 2019 11:30 JST
 
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan
February 27 2019 10:52 JST
 
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
February 21 2019 13:50 JST
 
More Press release >>

Latest Press Release


More Latest Release >>